Skip to Main Content

Paper Details

A Phase 1/2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Muscle-Invasive Bladder Cancer.
Clin Genitourin Cancer
3
2023
Cisplatin, Gemcitabine, Grapefruit, MIBC, Muscle-Invasive Bladder Cancer, NAC, Patients, Rapamycin, TME, cisplatin, gemcitabine, mTOR, muscle-invasive bladder cancer, pCR, patients, rapamycin, tumor, tumor cells
Author NameAffiliation
Jonathan L WrightUniversity of Washington, WA Fred Hutchinson Cancer Research Center
Daniel W LinUniversity of Washington, WA Fred Hutchinson Cancer Research Center
Peter S NelsonUniversity of Washington, WA Fred Hutchinson Cancer Research Center
Peter S NelsonUniversity of Washington, WA Fred Hutchinson Cancer Research Center
Elahe A Mostaghel
Heather H ChengUniversity of Washington, WA Fred Hutchinson Cancer Research Center
John L GoreUniversity of Washington, WA Fred Hutchinson Cancer Research Center
Evan Y YuUniversity of Washington
Bruce MontgomeryUniversity of Washington
  • 1 - 9

Datasets

Release 1.2